Abstract:PURPOSE:KH902 is a fusion protein which combines ligand binding elements taken from the extracellular domains of vascular endothelial growth factor (VEGF) receptors 1 and 2 and the Fc portion of IgG1. This study is designed to examine the inhibitory effect of KH902 in the choroidal neovascularization (CNV) monkey model.METHODS:The binding affinity with VEGF was measured by using the human VEGF ELISA kit, and the biological activity effect of KH902 was assayed by an in vitro inhibition experiment on human umbilical vein endothelial cell proliferation that was induced by VEGF. The experimental CNV was induced by causing perimacular laser injury in the eyes of rhesus monkeys and confirmed by fluorescence fundus angiography (FFA), optical coherence tomography (OCT), and multifocal electroretinograms (mf-ERG) 20 days after the infliction of the laser injury. KH902 was delivered to the animals through intravitreal injection at various doses. Monkeys were observed four weeks after injection by ophthalmic examination, FFA, OCT, mf-ERG, histopathology, and immunohistochemistry analysis.RESULTS:KH902 binds VEGF at a high affinity with a mean of IC(50) of 10 pM. KH902 at 41 nM can completely block VEGF-induced cell proliferation and KH902 at 10.7 nM can block 82.6% of cell growth. In the eyes of the treatment group, which received 300 microg and 500 microg KH902, choroidal neovascularization leakage was obviously less than before injection, and no leakage was observed at the end of the observation after injection. No high reflect light echogenic mass was detected by OCT. However, in the 0.1 mg KH902-treated and control eyes, the leakage and high reflect light echogenic mass still existed. The reduction of experimental CNV was greater in eyes treated with 300 microg and 500 microg KH902 than in eyes treated with 0.1 mg KH902 and the control eyes. There were fiber-vasculosa membrane proliferation in the 100 microg KH902-treated eyes and control eyes but not in the 300 microg and 500 microg KH902-treated eyes under histopathologic observation. The results of mf-ERG demonstrated that there was greater improvement in the 300 microg and 500 microg KH902-treated eyes than in the 100 microg KH902-treated eyes and control eyes.CONCLUSIONS:KH902 presents high affinity with VEGF and inhibitory activity on the proliferation of human umbilical vein endothelial cells (HUVECs) induced by VEGF. A single 300 microg or 500 microg KH902 intravitreal injection effectively inhibited leakage and growth of the CNV in rhesus monkeys without evidence of toxicity. This study suggests that KH902 has promise as a local antiangiogenic treatment of CNV.

Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.

A peptidic network antibody inhibits both angiogenesis and inflammatory response

Inhibition Of Pathologic Corneal Neovascularization By Topical Application Of A Novel Peptide In Vivo

Dual Blockade of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF-2) Exhibits Potent Anti-Angiogenic Effects.

Progress in Research on the Role of FGF in the Formation and Treatment of Corneal Neovascularization

A Synergistic Therapy with Antioxidant and Anti‐VEGF: Towards Its Safe and Effective Elimination for Corneal Neovascularization

A Synergistic Therapy with Antioxidant and Anti-VEGF: Toward Its Safe and Effective Elimination for Corneal Neovascularization

Recombinant Anti-Vascular Endothelial Growth Factor Fusion Protein Efficiently Suppresses Choridal Neovasularization in Monkeys.

Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903

Inhibition Of Pathological Corneal Neovascularization By A Small Peptide Derived From Human Apolipoprotein (A) Kringle V

[The Effectiveness and Safety Evaluation of Anti-Vegf Drugs on the Treatment of Corneal Neovascularization].

Combination of Vascular Endothelial Growth Factor Receptor/platelet-Derived Growth Factor Receptor Inhibition Markedly Improves the Antiangiogenic Efficacy for Advanced Stage Mouse Corneal Neovascularization

AA092, an Annonaceous Acetogenin Mimetic, Attenuates Angiogenesis in a Mouse Model of Inflammation-Induced Corneal Neovascularization

Exosome-Mediated Delivery of an Anti-Angiogenic Peptide Inhibits Corneal Neovascularization via VDAC1 and Autophagy

Therapeutic effects of a novel PIGF-1 derived peptide, ZY-1, on corneal neovascularization in vitro and in vivo.

Innovative platelet-derived extracellular vesicle drug delivery system for the treatment of corneal neovascularization

An injectable thermosensitive hydrogel for dual delivery of diclofenac and Avastin® to effectively suppress inflammatory corneal neovascularization

[Antisense Vascular Endothelial Growth Factor Suppressed Corneal Neovascularization in Rats].

Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo